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Left atrial appendage occlusion
Magnetic resonance imaging
a b s t r a c t
Background: There is increasing interest in performing left atrial appendage (LAA) occlusion at the time
of atrial ﬁbrillation (AF) ablation procedures. However, to date there has been no description of the acute
changes to the LAA immediately following pulmonary vein (PV) isolation and additional left atrium (LA)
substrate modiﬁcation. This study assessed changes in the size and tissue characteristics of the LAA
ostium in patients undergoing PV isolation.
Methods: This series included 8 patients who underwent cardiovascular magnetic resonance evaluation
of the LA with delayed enhancement magnetic resonance imaging and contrast enhanced 3-D magnetic
resonance angiography pre-, within 48 h of, and 3 months post ablation. Two independent cardiac
radiologists evaluated the ostial LAA diameters and area at each time point in addition to the presence of
gadolinium enhancement.
Results: Compared to pre-ablation values, the respective median differences in oblique diameters and
LAA area were þ1.8 mm, þ1.7 mm, and þ0.6 cm2 immediately post ablation (all NS) and 2.7 mm,
2.3 mm, and 0.5 cm2 at 3 months (all NS). No delayed enhancement was detected in the LAA post
ablation.
Conclusion: No signiﬁcant change to LAA diameter, area, or tissue characteristics was noted after PV
isolation. While these ﬁndings suggest the safety and feasibility of concomitant PV isolation and LAA
device occlusion, the variability in the degree and direction of change of the LAA measurements
highlights the need for further study.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Atrial ﬁbrillation (AF) is a common condition that is associated
with a 5-fold increased risk of stroke [1]. While oral anticoagulants
have traditionally been utilized for stroke reduction in AF patients,
their use has been suboptimal because of concerns over bleeding
[2]. Catheter ablation [3–5] and left atrial appendage (LAA)
occlusion [6] may reduce stroke risk without the need for oral
anticoagulation. The mechanism of the former is related to sinus
rhythm maintenance, whereas the latter acts through exclusion of
the LAA, which is the dominant site of thrombus formation in
patients with non-valvular AF [7,8]. As the long-term freedom
from AF associated with catheter ablation procedures is not ideal
[9], an appealing solution for stroke reduction would be the
placement of an LAA occlusion device at the time of an AF ablation
procedure. Such a combined approach may result in very low rates
of stroke, potentially similar to those reported in patients under-
going surgical MAZE procedures with LAA ligation [10,11], as well
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as minimize the need for a repeat invasive procedure requiring
transseptal catheterization.
To date, one small series evaluating the feasibility of LAA
occlusion at the time of catheter ablation comprising pulmonary
vein (PV) isolation has been published [12,13]. In addition, we know
of two clinical trials currently under way that are evaluating the
merits of this combined strategy (LAALA-AF Registry [14] and LAA
Occlusion after catheter ablation of AF (Clinical Trials.gov identiﬁer
number: NCT01695824) [15]). However, despite the enthusiasm
among electrophysiologists for simultaneous PV isolation and LAA
occlusion, it is unknown whether PV isolation triggers morphologic
changes of the LAA that may affect the ability to safely perform
concomitant LAA occlusion. That is, radiofrequency (RF) ablation in
the region of the left PV may alter the size, shape, and tissue
characteristics of the LAA ostium. Knowledge of any such changes
would be important as it may affect the approach to and safety of
percutaneous LAA occlusion at the time of an ablation procedure,
thereby inﬂuencing future clinical studies in this ﬁeld. In this pilot
study, we address this knowledge gap by reporting on changes in
the size and tissue characteristics of the LAA os in patients under-
going PV isolation and additional left atrium (LA) substrate mod-
iﬁcation as assessed using gadolinium-enhanced cardiovascular
magnetic resonance imaging (CMR).
2. Material and methods
Patients who underwent a ﬁrst-ever RF catheter ablation pro-
cedure for AF and were evaluated by CMR pre-, up to 48 h after, and
3 months post procedure were included in this study. Consent for
participation was obtained from each patient. Ethics approval was
obtained from the Sunnybrook Health Sciences Center Research
Ethics Board (Study Number: 357-2006; Initial Approval Date:
September 18th 2006; Study Closure Date: October 2013).
2.1. Ablation procedure
Catheter ablation was performed with either a manual or
robotic (Stereotaxis Niobe Remote Magnetic Navigation System,
St. Louis, USA) approach using an irrigated RF ablation catheter
and a 3D-electroanatomic mapping system. Fluoroscopy and the
created 3D-electroanatomic maps were used to guide catheter
manipulation and ablation in the region of the PVs. Ablation was
typically performed along the venous side of the ridge when
ablating the anterior aspect of the left PV (Fig. 1). Irrigated RF
ablation was typically performed for 30 s at each site with a
maximum power of 40 W and temperature of 481. The goal of
pulmonary venous ablation was the elimination of high frequency
local electrograms with subsequent PV isolation. Additional LA
substrate modiﬁcation was performed at the operator's discretion.
No patients underwent electrical isolation of the LAA, LA substrate
modiﬁcation in the region of the LAA, or ablation within the distal
coronary sinus or ligament of Marshall. Recurrence of any atrial
arrhythmia during follow-up was determined using intermittent
Holter, Loop, and electrocardiography monitoring.
2.2. Magnetic resonance imaging data acquisition
All images were acquired on a 1.5 T Twinspeed Signa magnetic
resonance (MR) scanner (GE Healthcare, Inc., Milwaukee, Wisconsin).
In all patients, a contrast-enhanced 3D MR angiography (CE-3D MRA)
data set was acquired in the coronal orientation following a 13 cc
gadolinium chelate injection (Gadobutrol, Bayer Healthcare, Berlin,
Germany). To measure the delay time, a test bolus repeating a single
axial 2D spoiled gradient echo (2D FSPGR) slice was used after a 1 cc
contrast injection. Representative imaging parameters for the 2D
FSPGR were as follows: repetition time (TR)/echo time (TE)¼13/min,
ﬂip angle¼901, sampling matrix¼128128 pixels, number of excita-
tions (NEX)¼1, ﬁeld of view (FOV)¼38mm, and slice thick-
ness¼10mm/0 gap. The parameters for the CE-3D MRA sequence
were as follows: TR/TE¼3.8/1.3 ms, ﬂip angle¼451, sampling
matrix¼320160 pixels, NEX¼1, FOV¼380mm, 34 locations/slab,
slice thickness¼5mm, and a breath hold time of 20 s. This sequence
was acquired twice after a single contrast injection. The inversion
recovery (IR)-prepared delayed enhancement MRI (DE-MRI) was
obtained in a sagittal oblique plane approximately 20 min after
contrast injection. Imaging parameters were as follows: free-
breathing navigator gating, TR/TE¼5.1/1.6 ms, ﬂip angle¼251,
sampling matrix¼256256 pixels, FOV¼350mm, and slice thick-
ness¼3.4 mm. An inversion time was selected using a Cine-IR pulse
sequence prior to the delayed enhancement scan.
2.3. Image analysis
Images were analyzed using commercially available software
(Aquarius, Intuition v4.4.8, TeraRecon, Inc., Foster City, California).
Two experienced cardiac radiologists independently created mul-
tiplanar reformatted images using the double oblique technique
(Fig. 2). The “full-width at half maximum” technique of image
contrast and brightness adjustment was applied to ensure mea-
surement consistency and reproducibility [16]. The os of the LAA
was deﬁned as the site of reﬂection of this structure with the
adjacent LA [17]. Measurements of the LAA ostial diameter were
obtained in 2 orthogonal views (D1, D2) (Fig. 2). The area of the
LAA at the os was determined by manual planimetry of the LAA os.
To minimize bias, each radiologist was blinded to the timing of
imaging relative to the ablation procedure.
Fig. 1. Ablation along the venous side of the left Pulmonary vein – left atrial appendage (PV-LAA) ridge. 3D electroanatomic map reconstruction of the LA and LAA with the
NavX (St. Jude Medical, Minneapolis, USA) electroanatomic mapping system. Panel A: Anterior–posterior top-down view showing the relationship between the left PVs
(green), the LAA (red), and the sites where ablation lesions are placed (brown dots). Panel B: Sagittal clipping plane showing the relationship between the left PVs (green),
the LAA (red), and the sites where ablation lesions are placed (brown dots).
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To assess whether differences in measured values were simply
due to measurement error, we determined the mean absolute
difference between the two radiologists for measurements of the
LAA diameter (D1 or D2 at all time points) and LAA area (at all
time points).
Each cardiac radiologist independently evaluated the presence
of gadolinium enhancement within the LA, and speciﬁcally within
the ostial region of the LAA. Again, each radiologist was blinded to
the timing of imaging relative to the ablation procedure. Finally,
measurements of all PVs were obtained to assess for radiographic
evidence of PV stenosis (deﬁned as a 450% reduction in the PV
diameter [18]).
2.4. Statistical analysis
Continuous variables are reported as median and range. The
mean of the pair of values for LAA diameter (D1 and D2) and of the
LAA area at each time point were calculated. The mean absolute
measurement difference (for both diameters and the area) at all
time points between the two cardiac radiologists was determined
to provide insight into variability related to the measurement
process. A paired analysis of the mean repeated measures was
conducted using ANOVA with signiﬁcance determined using the
Wilcoxon test. P-values o0.05 were considered statistically sig-
niﬁcant. Statistical analysis was performed with R (Version 3.02,
Auckland, New Zealand).
3. Results
Eight patients were imaged at all three time points. The median
age was 58 years (range: 48–76) and all patients were male. Six of
the patients paroxysmal AF, 3 had hypertension, and none had
diabetes. The LA diameter on echocardiography was 41 mm
(range: 34–53). All patients underwent irrigated RF ablation, and
in 4 the procedure was performed with a robotic approach. The
median total RF ablation time for each case was 4134 s (range:
3040–4786). No patient developed PV stenosis after the procedure.
Long-term freedom from recurrent atrial arrhythmia was noted in
5 of the 8 patients.
A pre-procedure CMR was performed 128 days (range: 1–218)
pre-ablation. The immediate post-ablation MRI was performed the
following day in 7 patients and 2 days post ablation in the remaining
patient. Delayed imaging was performed 67 days (range: 57–103)
post ablation. Imaging was performed in sinus rhythm for 7 patients
at each study point, and in AF for the eighth patient.
Fig. 3 shows the change in the LAA diameters and area for each of
the 8 patients. Compared to pre-ablation values, the respective
median differences in the D1 diameter, D2 diameter, and LAA area
were þ1.8 mm, þ1.7 mm, and þ0.6 cm2 immediately post ablation
(all NS) and 2.7 mm, 2.3 mm, and 0.5 cm2 at 3 months (all NS).
Inter-patient variability in the degree and direction of change in the
D1 and D2 diameters and the LAA area at the two post-ablation time
points was apparent (Fig. 3).
The mean absolute differences between the two radiologists for
measurements of the LAA diameter (D1 or D2 at all time points)
and LAA area (at all time points) were 2.4 mm and 0.7 cm2,
respectively.
Delayed enhancement was not present in any patient pre
ablation but was present within the LA and pulmonary venous
antrum in all patients post ablation (Fig. 4). No patient showed
evidence of delayed enhancement within the LAA at any time
point. Of note, 1 patient had evidence of delayed enhancement
along the pulmonary venous ridge immediately post ablation, but
not within the LAA itself (Fig. 4, Panel B).
4. Discussion
The results of this pilot imaging study suggest that LAA ostial
dimensions and tissue characteristics are unaltered following PV
isolation and LA substrate modiﬁcation. These ﬁndings, which may
appear obvious to some, are important to document given the
increased enthusiasm among electrophysiologists for performing
concomitant LAA occlusion and PV isolation.
Current techniques for percutaneous endocardial LAA occlusion
rely on attempting occlusion by deploying devices within the
ostial region of the LAA. While differences exist between commer-
cially available percutaneous devices, common features include
their placement generally at or slightly distal to the os of the LAA
and the use of stabilizing barbs that aid in anchoring the device to
the adjacent tissue [19]. Therefore, it is important to obtain
knowledge of any alteration of the LAA ostial size or tissue
characteristics of the LAA wall during an AF ablation procedure
prior to proceeding with LAA device occlusion at the time of PV
isolation.
The magnitude of the changes observed at all time points
throughout our pilot study is probably not clinically important and
is potentially related to inherent inaccuracies in measurement.
Furthermore, these changes may not affect device implantation
given the practice of “over-sizing,” that is, selecting a percutaneous
LAA device with a diameter 10–20% larger than the largest
measured LAA dimension [12,19]. However, the variability in the
magnitude of change observed between patients in our pilot study
coupled with the consequences of inappropriate LAA device sizing
highlights the need for further study in a larger patient population.
DE-MRI has been shown to identify atrial myocardium changes
after ablation procedures [20–22]. Gadolinium diffuses into the extra-
cellular space created by myocardial edema, a reversible form of
myocardial injury, as well as into the intracellular space with loss of
Fig. 2. Measurement of the LAA ostial diameters and area. Contrast-enhanced three-dimensional magnetic resonance angiography using the “full-width at half maximum”
method of windowing. Panels A and B: Multi-planar reformatted images through the LAA ostium obtained using the “double oblique” technique. Panel C: Two orthogonal
dimensions of the LAA ostium (D1, D2) were obtained and the area of the LAA at the ostium was also determined by manual planimetry.
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cell membrane integrity [20,23], which may correspond to varying
degrees of coagulation necrosis and intra-lesional hemorrhage [24].
Owing to the inaccuracies associated with catheter localization and
stability relating to the presence of cardiac and respiratory motion, RF
energy may be unintentionally delivered within the region of the LAA
during ablation of the anterior portion of the left PVs. The presence
of acute RF tissue injury in this region may be a deterrent to the
implantation of an LAA occlusion device, as edematous or necrotic
tissue may lead to device instability, resulting in device emboli-
zation or LAA perforation secondary to device over-sizing or to the
inadvertent positioning of a barb within friable tissue. To the best
of our knowledge, our work is the ﬁrst to evaluate the presence
Fig. 3. LAA ostial dimensions pre-, post-, and 3 months post-ablation. LAA ostial dimensions for each patient pre ablation, immediately following ablation, and 3 months
(delayed) post ablation. Panel A: Ostial diameter (D1) measurement. Panel B: Ostial diameter (D2) measurement. Panel C: Ostial area.
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of gadolinium enhancement in the region of the LAA, and suggests
that the LAA likely remains free of signiﬁcant RF injury despite
ablation to the adjacent left PV. While this ﬁnding may appear
intuitive, it is important to conﬁrm this intuition as one would want
to be conﬁdent that the LAA is free of injury prior to the placement of
an LAA occlusion device.
The aim of our work was not to advocate for performing LAA
occlusion and AF ablation concomitantly. Indeed, given the potential
beneﬁts of a successful catheter ablation procedure for stroke reduc-
tion [3–5], some would appropriately advocate performing these
procedures in a staged fashion. The aim of this report was simply to
provide an objective characterization of the LAA after PV isolation and
additional substrate modiﬁcation. Our ﬁndings will provide reassur-
ance to interventional cardiac electrophysiologists contemplating
concomitant AF ablation and percutaneous LAA occlusion. This knowl-
edge is important, as combined procedures may have theoretical
advantages including a reduction in the number of procedures
requiring transseptal catheterization, truncation of the total required
duration of oral anticoagulation (as post-procedure anticoagulation
would serve a dual purpose of preventing both post-ablation stroke
and acute thrombus formation on the LAA occlusion device), and the
potential for a long-term reduction in stroke risk without the need for
oral anticoagulation. While our current pilot study is important and
addresses an important gap in clinical knowledge, it merely provides
radiographic data and is no substitute for the additional larger clinical
studies needed to elucidate the feasibility and safety of performing
these procedures concomitantly prior to the widespread uptake of
combined procedures.
Limitations to our work must be noted. First, our sample size was
small and comprised patients without severe LA dilation, which may
have prevented the detection of statistically signiﬁcant changes in
LAA dimensions. While we suspect that changes in LAA dimension
may not be of a sufﬁcient magnitude to affect LAA occlusion device
placement, we cannot fully exclude this possibility in all patients and
for all ablation strategies and ablation energies. Second, our approach
to PV isolation involved ablation along the venous side of the ridge,
frequently with the precision of robotic navigation. Deliberate abla-
tion along the pulmonary venous ridge itself, the appendage side of
the ridge, or even ablation resulting in LAA electrical isolation may
have a more prominent inﬂuence on the LAA. Despite this, given the
recent uptake of circular ablation techniques that result in more
ostial ablation, our ﬁndings are applicable [25]. Third, LAA imaging
was not performed immediately after ablation. This delay in imaging
may have resulted in an underestimation of acute RF injury, which
may have resolved during the short waiting period. In addition, our
measurements obtained at 24 h post ablation may not reﬂect acute
LAA dimensions due to changes in ﬂuid status. Finally, while it may
be argued that the absence of gadolinium uptake in the LAA may
reﬂect technical limitations of DE-MRI and not the absence of actual
LAA injury, we suspect that this is not the case as all patients had
gadolinium enhancement in other areas of the LA post ablation.
5. Conclusion
The dimensions and tissue characteristics of the LAA remain
relatively unchanged after PV isolation and LA substrate modiﬁca-
tion. Further study is needed to conﬁrm these ﬁndings prior to
widespread recommendations of concomitant AF ablation and LAA
device occlusion procedures.
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